专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014081878A3 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL 审中-公开
标题翻译：用于调节细胞增殖，分化和存活的替代三唑基 - 吡啶化合物
公开(公告)号：WO2014081878A3
公开(公告)日：2014-07-17
申请号：PCT/US2013071084
申请日：2013-11-20
申请人： STATEGICS INC
发明人： PUNNONEN JUHA , SPENCER JEFFREY R , CHURCH TIMOTHY J , TETTENBORN CONNIE S , LARIOSA-WILLINGHAM KAREN , LEONOUDAKIS DIMITRI , MILLER JAMES L
IPC分类号： A61K31/519
CPC分类号： C07D487/04
摘要： Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.
摘要翻译：本文公开了式I的红细胞生成素模拟化合物，其调节例如肾细胞，神经元，红细胞或其它促红细胞生成素反应性细胞的存活，功能或分化。本发明还涉及优先调节表达组织保护性促红细胞生成素受体的细胞的化合物和方法。本发明的化合物可用于预防和治疗诸如贫血，器官损伤和中枢神经系统疾病之类疾病，以及细胞治疗如干细胞疗法的辅助。

2. 发明申请

WO2008070583A3 THROMBOPOIETIN MIMETICS 审中-公开
标题翻译： THROMBOPOIETINMIMTCS
公开(公告)号：WO2008070583A3
公开(公告)日：2008-08-14
申请号：PCT/US2007086186
申请日：2007-11-30
申请人： STATEGICS INC , SPENCER JEFFREY R , PUNNONEN JUHA
发明人： SPENCER JEFFREY R , PUNNONEN JUHA
IPC分类号： A61K31/655
CPC分类号： C07D231/46 , C07D401/12
摘要： The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.
摘要翻译：本发明涉及化合物及其在治疗由免疫性血小板减少性紫癜，癌症化疗，手术，骨髓或干细胞移植，放射性损伤或治疗，慢性病毒感染和全血细胞减少等疾病或病症引起的血小板减少症中的用途。本发明进一步涉及含有本发明化合物和组合物的药物组合物，以及通过向该哺乳动物施用有效量的选择的血小板生成素受体激动剂来治疗哺乳动物（包括人）中的这些疾病或病症的方法。

3. 发明申请

WO2014081878A2 SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS FOR MODULATING CELL PROLIFERATION, DIFFERENTIATION AND SURVIVAL 审中-公开
标题翻译：用于调节细胞增殖，分化和存活的取代三唑基 - 嘧啶化合物
公开(公告)号：WO2014081878A2
公开(公告)日：2014-05-30
申请号：PCT/US2013/071084
申请日：2013-11-20
申请人： STATEGICS, INC.
发明人： PUNNONEN, Juha , SPENCER, Jeffrey, R. , CHURCH, Timothy, J. , TETTENBORN, Connie, S. , LARIOSA-WILLINGHAM, Karen , LEONOUDAKIS, Dimitri , MILLER, James, L.
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.
摘要翻译：本文公开了式I的促红细胞生成素模拟化合物，其调节例如肾细胞，神经元，红系细胞或其他促红细胞生成素应答细胞的存活，功能或分化。本发明还涉及优先调节表达组织保护性促红细胞生成素受体的细胞的化合物和方法。本发明化合物可用于预防和治疗诸如贫血，器官损伤和中枢神经系统疾病的疾病，以及作为细胞治疗（例如干细胞疗法）的辅助手段。

4. 发明申请

WO2008070583A2 THROMBOPOIETIN MIMETICS 审中-公开
公开(公告)号：WO2008070583A2
公开(公告)日：2008-06-12
申请号：PCT/US2007/086186
申请日：2007-11-30
申请人： STATEGICS, INC. , SPENCER, Jeffrey, R. , PUNNONEN, Juha
发明人： SPENCER, Jeffrey, R. , PUNNONEN, Juha
IPC分类号： C07D401/10 , C07D231/46 , A61K31/454 , A61K31/4152 , A61P25/00 , A61P9/00
CPC分类号： C07D231/46 , C07D401/12
摘要： The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.
摘要翻译：本发明涉及化合物及其在治疗由诸如免疫性血小板减少性紫癜，癌症化疗，手术，骨髓或干细胞移植，放射损伤或治疗，慢性疾病或病症等疾病或病症引起的血小板减少症中的用途。病毒感染和全血细胞减少症。本发明进一步涉及含有本发明化合物和组合物的药物组合物，以及通过给予这种哺乳动物有效量的选择性血小板生成素受体激动剂治疗哺乳动物（包括人）的此类疾病或病症的方法。 p>

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式